Eulav Asset Management Vertex Pharmaceuticals Inc Transaction History

Eulav Asset Management

$4.11 Billion
Q3 2024

A detailed history of Eulav Asset Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Eulav Asset Management holds 31,500 shares of VRTX stock, worth $14.2 Million. This represents 0.36% of its overall portfolio holdings.

Number of Shares

31,500

Previous 36,000 12.5%

Holding current value

$14.2 Million

Previous $16.9 Million 13.17%

% of portfolio

0.36%

Previous 0.46%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$460.0 - $505.78 $2.07 Million - $2.28 Million	-4,500 Reduced 12.5%	31,500 $14.7 Million
Q2 2024 Aug 13, 2024	SELL	$392.81 - $485.53 $746,339 - $922,507	-1,900 Reduced 5.01%	36,000 $16.9 Million
Q1 2024 May 30, 2024	SELL	$407.69 - $446.08 $203,845 - $223,040	-500 Reduced 1.3%	37,900 $15.8 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $1.72 Million - $2.05 Million	5,000 Added 14.97%	38,400 $15.6 Million
Q3 2023 Nov 13, 2023	SELL	$338.18 - $362.46 $710,178 - $761,166	-2,100 Reduced 5.92%	33,400 $11.6 Million
Q2 2023 Aug 09, 2023	SELL	$314.42 - $351.91 $628,840 - $703,820	-2,000 Reduced 5.33%	35,500 $12.5 Million
Q1 2023 Apr 27, 2023	SELL	$283.23 - $323.1 $1.27 Million - $1.45 Million	-4,500 Reduced 10.71%	37,500 $11.8 Million
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $1.72 Million - $1.93 Million	-6,010 Reduced 12.52%	42,000 $12.1 Million
Q3 2022 Nov 03, 2022	SELL	$273.83 - $305.53 $1.64 Million - $1.83 Million	-5,998 Reduced 11.11%	48,010 $13.9 Million
Q2 2022 Jul 22, 2022	SELL	$234.96 - $292.55 $1.41 Million - $1.76 Million	-5,999 Reduced 10.0%	54,008 $15.2 Million
Q1 2022 May 10, 2022	SELL	$221.42 - $260.97 $4.43 Million - $5.22 Million	-19,993 Reduced 24.99%	60,007 $15.7 Million
Q4 2021 Feb 11, 2022	SELL	$177.01 - $223.45 $4.96 Million - $6.26 Million	-28,000 Reduced 25.93%	80,000 $17.6 Million
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $6.17 Million - $6.9 Million	-34,000 Reduced 23.94%	108,000 $19.6 Million
Q2 2021 Aug 06, 2021	SELL	$187.49 - $221.1 $1.5 Million - $1.77 Million	-8,000 Reduced 5.33%	142,000 $28.6 Million
Q1 2021 Apr 30, 2021	BUY	$207.02 - $241.31 $14.9 Million - $17.4 Million	72,000 Added 92.31%	150,000 $32.2 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $6.52 Million - $8.7 Million	31,500 Added 67.74%	78,000 $18.4 Million
Q3 2020 Nov 05, 2020	SELL	$255.65 - $303.1 $5,113 - $6,062	-20 Reduced 0.04%	46,500 $12.7 Million
Q2 2020 Aug 11, 2020	SELL	$225.48 - $295.8 $1.01 Million - $1.33 Million	-4,480 Reduced 8.78%	46,520 $13.5 Million
Q1 2020 Apr 27, 2020	SELL	$199.77 - $247.81 $1.4 Million - $1.73 Million	-7,000 Reduced 12.07%	51,000 $12.1 Million
Q4 2019 Feb 13, 2020	SELL	$166.71 - $223.91 $1.83 Million - $2.46 Million	-11,000 Reduced 15.94%	58,000 $12.7 Million
Q3 2019 Nov 12, 2019	BUY	$166.23 - $187.09 $11.5 Million - $12.9 Million	69,000 New	69,000 $11.7 Million
Q1 2019 May 13, 2019	SELL	$163.73 - $194.7 $1.15 Million - $1.36 Million	-7,000 Reduced 8.86%	72,000 $13.4 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $2.43 Million - $3.08 Million	-16,000 Reduced 16.84%	79,000 $13.1 Million
Q3 2018 Oct 26, 2018	SELL	$167.73 - $192.74 $17.9 Million - $20.6 Million	-107,000 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$145.72 - $169.96 $1.46 Million - $1.7 Million	-10,000 Reduced 8.55%	107,000 $18.2 Million
Q1 2018 May 09, 2018	SELL	$151.6 - $177.13 $2.43 Million - $2.83 Million	-16,000 Reduced 12.03%	117,000 $19.1 Million
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $1.1 Million - $1.24 Million	8,000 Added 6.4%	133,000 $19.9 Million
Q3 2017 Nov 14, 2017	SELL	$148.13 - $162.24 $592,520 - $648,960	-4,000 Reduced 3.1%	125,000 $19 Million
Q2 2017 Aug 14, 2017	BUY	N/A	129,000	129,000 $16.6 Million

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eulav Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Eulav Asset Management with notifications on news.

Account

Eulav Asset Management Vertex Pharmaceuticals Inc Transaction History